A US district court did not err in ruling that two US patents shielding Bristol Myers Squibb and Pfizer’s Eliquis (apixaban) blockbuster were valid and infringed by abbreviated new drug applications filed by HEC’s Sunshine Lake Pharma, Sigmapharm and Unichem, the US Court of Appeals for the Federal Circuit has affirmed.
The Federal Circuit’s decision – which was issued after it deduced “no error, and certainly no clear error, in the district court’s findings of fact” – means that generic competition to the blockbuster
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?